Logo-npj
Submitted: 10 Jan 2019
Accepted: 14 May 2019
First published online: 10 Jul 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Nephropharmacol. 2020;9(1): ee08.
doi: 10.15171/npj.2020.08
  Abstract View: 56
  PDF Download: 91

Original

Correlation of serum soluble Klotho with fibroblast growth factor 23 levels in chronic kidney disease patients; a single centre study

Yuvaraj Anand 1, Vijayan Madhusudan 1, Parthasarathy Rajeevalochana 1, Mathew Milly 1, George Deepu 1, Abraham Georgi 1 *

1 Institute of Kidney Diseases, Urology and Organ Transplantation, Madras Medical Mission, Chennai, India
*Corresponding author: Abraham Georgi, Email: Email: abraham_georgi@yahoo.com

Abstract

Introduction: Klotho is a single-pass transmembrane protein with a long extracellular domain and short cytoplasmic tail that appears to modulate aging.

Objectives: This cross-sectional investigation was conducted at a tertiary care centre to find the possible correlation of serum Klotho with various biochemical parameters in Indian chronic kidney disease (CKD) patients.

Patients and Methods: The study was conducted in 80 CKD patients (58 males, 22 females). Mean age was 54.21 ± 14.08 years (25-90 years). Participants included 55 CKD- hemodialysis (HD), 10 CKD- peritoneal dialysis (PD) and 15 CKD-non-dialysis (ND) patients.

Results: Serum Klotho (sKlotho) in CKD-HD patients ranged from 0 to 374.36 ng/mL with a mean of 13.76±4.3 ng/mL (median: 0.0174 ng/mL). In PD patients, sKlotho ranged from 0 to 374.36 ng/ mL with a mean of 37.58 ± 6.56 ng/mL (median of 0.0087 ng/mL). In ND population, sKlotho ranged from 0 to 7.01 ng/mL, with a mean of 0.73 ± 0.01 ng/mL (median of 0.1687ng/mL). In CKDHD and CKD-PD patients, sKlotho was positively correlated with the fibroblast growth factor 23 (pg/mL) (P<0.001).

Conclusion: Serum Klotho levels show significant positive correlation with FGF23 levels in HD and PD patients. The findings of the study indicate that high Klotho and fibroblast growth factor 23 levels may be associated with worse outcomes in chronic renal failure patients

Keywords: Klotho, Chronic kidney disease, Chronic kidney disease, Fibroblast growth factor

Implication for health policy/practice/research/medical education:

Serum Klotho has emerged as a powerful player in calcium-phosphate homeostasis, contributing to the high burden of cardiovascular disease in chronic kidney disease patients. The findings of the study indicate that high Klotho and fibroblast growth factor 23 levels may be associated with worse outcomes in chronic kidney disease patients.

Please cite this paper as: Anand Y, Madhusudan V, Rajeevalochana P, Milly M, Deepu G, Georgi A. Correlation of serum soluble Klotho with fibroblast growth factor 23 levels in chronic kidney disease patients; a single centre study. J Nephropharmacol. 2019;8(2):x-x. DOI: 10.15171/jrip.2019.xx

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 56

Your browser does not support the canvas element.


PDF Downloaded: 91

Your browser does not support the canvas element.